The rate of obesity among US women has been increasing, and obesity is associated with increased risk of surgical site infection (SSI) following cesarean delivery. The optimal perioperative antibiotic prophylactic regimen in this high-risk population undergoing cesarean delivery is unknown.
H ealth care-associated infections are the most common complications of hospital care and contribute to significant health care costs, patient morbidity, and mortality. These infections affected an estimated 2 million individuals in 2014 based on national data from acute care and long-term hospitals and rehabilitation facilities. 1 
]).
Routine use of preoperative cephalosporin antibiotics has been shown to decrease the risk of SSI and is considered the standard of care. 7, 8 Obesity is an independent risk factor for SSI despite recommended preoperative antibiotic regimens.
9
Limited studies have addressed optimal antibiotic regimens for the prevention of SSI among obese women. Preoperative cefazolin dose adjustments (2 g vs 3 g) have demonstrated higher antibiotic tissue concentrations but have not demonstrated clinical improvements in rates of SSI. [10] [11] [12] [13] Various postpartum antibiotic combinations and durations have been studied with conflicting benefit, but no studies have specifically addressed the obese population.
14,15
The objective of this trial was to determine the effect of an additional 48-hour course of postoperative, prophylactic oral cephalexin plus metronidazole compared with the current standard preoperative intravenous cephalosporin alone on SSI among obese women after cesarean delivery.
Methods

Trial Design
This study was a single-center, double-blind, randomized clinical trial conducted to determine the efficacy of postoperative, prophylactic oral cephalexin plus metronidazole compared with placebo for 48 hours after cesarean delivery for the prevention of SSI among obese women who receive standard preoperative cefazolin prophylaxis. The study was approved by the University of Cincinnati Institutional Review Board. Written informed consent of study participants was obtained preoperatively or within 8 hours after cesarean delivery, followed by immediate randomization. Because the cesarean surgical approach was standardized for the study, the principal investigator set a predetermined study enrollment deadline to avoid potential changes in practice patterns that may occur with prolonged study duration. The complete trial protocol is available in Supplement 1.
Cesarean surgical approach was standardized at the study institution prior to the start of this trial according to evidencebased practice at the time of study conception. 16 All participants received chlorhexidine skin preparation, unless there was a documented allergy in which case povidone-iodine would be used. Standard sterile draping of participants was performed. Intravenous cefazolin (2 g) was administered prior to skin incision. A Pfannenstiel incision was the preferred skin incision. However, decisions regarding the type of skin incision were left to the discretion of primary surgeons and individualized to participants. The cesarean delivery was performed in standard accepted practice and the fascia was closed with a monofilament suture in a running-stitch fashion. 17 The subcutaneous layer was reapproximated with 3-0 polyglactin in either running or interrupted sutures if the depth measured 2 cm or more. Skin incisions were closed using 4-0 polyglactin or poliglecaprone in a subcuticular fashion unless a primary surgeon believed skin staples were superior for an individual case. Deviations from the outlined standardized surgical protocol were recorded and analyzed. Surgical dressings were removed 24 to 36 hours postoperatively. Incisions were examined daily in the hospital by labor and delivery physician teams.
Patient Selection and Randomization
Women with a prepregnancy BMI of 30 or higher, with a final plan for cesarean delivery, and aged at least 13 years who were admitted to the labor unit for delivery were approached for study participation. Study enrollment occurred between October 2010 and December 2015 and participants were followed up through February 2016. Exclusion criteria included known immunodeficiency syndromes, non-English speaking, known allergies to cephalosporin or metronidazole, or planned administration of antibiotics in the postpartum period for any medical or obstetric indication. Investigators, physicians, labor and postpartum staff, and participants remained blinded to treatment allocation through the entire duration of the study. All study participants received standard intravenous cefazolin (2 g) prior to surgical incision. After providing informed consent to participate in the trial, women were randomized to receive either a prophylactic 48-hour course of oral cephalexin, 500 mg, and oral metronidazole, 500 mg, or identicalappearing placebo, every 8 hours for a total of 6 doses of each
Key Points
Question Does postpartum prophylactic oral cephalexin and metronidazole decrease surgical site infection rates among obese women who receive standard preoperative antimicrobial prophylaxis and undergo cesarean delivery?
Findings In this randomized clinical trial among 403 obese women, the rate of surgical site infection within 30 days following cesarean delivery was 6% with oral cephalexin and metronidazole and 15% with placebo, a significant difference.
Meaning Among obese women who undergo cesarean delivery, use of prophylactic oral cephalexin and metronidazole may be warranted for prevention of surgical site infection.
antibiotic. The first dose of study medications was scheduled to be given 8 hours after intravenous cefazolin was administered. Study drug deviations were reported, including study drugs initiated more than 12 hours after administration of preoperative intravenous antibiotics, missed dose(s) of study drug, administration of study drugs more than 1 hour after the scheduled time of administration, and patient voluntary withdrawal from the study prior to the last scheduled dose.
Randomization scheme was stratified by membrane status prior to delivery (intact membranes vs rupture of membranes [ROM] ). The University of Cincinnati Medical Center, Office of Clinical Research, Investigational Pharmacy prepared separate randomization schemes for study participants with intact membranes and ROM using the Wichmann-Hill random number generator with blocks of 10.
18 Investigational medications and placebo preparations were blinded by overencapsulation in size 00 dark green opaque capsules. A small amount of lactose powder was added to capsules to minimize any movement within the capsule.
Study Outcomes
The primary study outcome was development of an SSI within 30 days of delivery. Surgical site infection was defined according to the National Healthcare Safety Network of the Centers for Disease Control and Prevention and comprised superficial incisional, deep incisional, or organ/ space infections (see eTable 1 in Supplement 2 for outcome definitions). 19 Prespecified secondary outcomes included any incisional morbidity, defined as any defect in the incisional integrity with or without the presence of an infection, including cellulitis, endometritis, and wound separation. Additional secondary outcomes included endometritis, cellulitis, fever of unknown etiology (any temperature greater than 38.3°C without an attributable source), and wound separation. Cellulitis was defined as an infection of the skin, underlying soft tissue, or both requiring antibiotics for treatment. Wound separation included any defect in the skin incision of at least 1 cm. Participants returned for postoperative evaluations at 2 and 6 weeks postpartum. Postpartum diagnoses of SSI were made by treating physicians and verified by chart review or discussion with diagnosing physicians by principal investigators or research registered nurses , who were unaware of the study group assignments. Follow-up examination visits included a detailed history and review of systems to screen for infection and medication adverse effects following delivery. Examination of patients' wounds determined evidence of wound separation, erythema, induration, or signs of wound abscess. Participants' vital signs were measured and a point-of-care urinalysis performed to assess for presence of urinary tract infection. Individuals who did not present for either the 2-or 6-week postpartum follow-up examination were called by a research registered nurse or investigator for a minimum telephone assessment, rescheduled for a follow-up visit, or both. Participants were questioned regarding pain at incision site, drainage from incision, fever symptoms, separation of incision, antibiotic administration after hospital discharge, and additional visits to any medical facility for incisional problems or potential medication-related concerns.
Data Collection and Blinding
Research registered nurses and study investigators obtained demographic and medical history and follow-up outcomes at the time of enrollment, following delivery, and postpartum. Study data were collected by 3 coinvestigators blinded to study group designation (A.M.V., S.R., and C.R.W.) and were managed using the Research Electronic Data Capture (REDCap) electronic data capture tools hosted at the Cincinnati Children's Hospital Medical Center. 20 REDCap is a secure web-based application designed to support data capture for research studies. Data pertinent to other potential risk factors for SSI were collected, including race/ethnicity, chronic hypertension, and diabetes. Maternal race/ethnicity was self-reported as an open-ended question on collection of the demographic information at the time of enrollment and confirmed upon data abstracted from the electronic medical record. Analysis of race/ethnicity was included because prior studies have demonstrated higher rates of SSI among black women. 21 The data were reviewed and cross-checked for accuracy by C.R.W. prior to data analysis. Statistical analyses were performed by E.D., who was blinded to study group designation and not involved in study recruitment or data collection. The data continued to be blinded until all statistical analyses were complete.
Statistical Analyses
A sample size was calculated to reflect a clinically and statistically meaningful difference in SSI rates between all obese women who received postcesarean antibiotics to those who received placebo. Prior to the designing of the study, the rate of SSI was 20% in the population of obese women undergoing cesarean delivery at our institution. The following assumptions were considered in the power analysis: 50% relative SSI reduction, baseline SSI rate of 20%, 10% rate of postpartum loss to follow-up, 2-sided α=.05, 80% power, and 1:1 ratio of exposed to unexposed. A relative risk reduction of 50% was chosen given studies available during study design that had demonstrated similar reductions with antibiotic prophylaxis, a reduction that was deemed to be clinically meaningful, and one that could potentially outweigh risks of expanded antibiotic use. 22, 23 The total sample size to detect a clinically relevant and moderately large effect size in SSI reduction was 438 participants. The primary outcome was reported as the difference in proportion of SSI between the cephalexin-metronidazole group and the placebo group. To quantify the effect of antibiotics on the dichotomous outcomes of SSI and other wound morbidities, a log-binomial model, the generalized linear model, with log link was used. The analysis was performed with an intention-to-treat principle, including participants lost to follow-up postpartum or with any study deviations. The number needed to treat to prevent 1 SSI was calculated.
Approximately 5% of patients had missing follow-up information on the primary outcome of SSI. To account for the potential influence of missing outcome data on risk estimates, a multiple imputation sensitivity analysis was performed. Multiple imputation using multivariate normal distribution with 10 imputations was used, achieving 99% relative efficiency and ensuring in-range values. A regression analysis was conducted on each imputed data set, which combines the results using a weighted average approach that accounts for the variation among imputed data sets.
Secondary outcomes were analyzed on an exploratory basis comparing the rates and differences in proportion of outcomes between the cephalexin-metronidazole and placebo groups with associated 95% confidence intervals.
Although randomization was stratified by membrane status, sample size calculations were not predetermined to represent subgroup comparisons. Therefore, post hoc analyses comparing SSI rates between women who received cephalexin-metronidazole vs those who received placebo in each subgroup (intact membranes or ROM) were performed to calculate the frequencies, differences, and 95% confidence intervals of primary and secondary outcomes among participants in the cephalexin-metronidazole group compared with placebo participants. A test of interaction was performed to analyze interaction between membrane status and the primary outcome.
Comparisons with a 2-sided P<.05 or 95% confidence interval without inclusion of the null were considered statistically significant. Statistical analysis was performed using Stata software, release 12 (Stata Corp).
Results
Study Population
Of the 1002 women who met BMI eligibility for the trial, 149 (14.9%) met at least 1 exclusion criteria, 378 (37.7%) declined study participation, and 71 (7.1%) were not approached, secondary to unavailable study staff to enroll the patient and obtain informed consent or concern about the patient's ability to provide informed consent or follow-up for postpartum care (Figure) .
A total of 404 study participants were enrolled, and 1 participant was excluded from analysis because her study group designation could not be determined. Enrollment was discontinued prior to achieving the targeted number of participants after reaching the predetermined study deadline that had been set by the principal investigator and approved by the institutional review board. The planned sample size was not achieved largely because of a higher-than-anticipated need to continue antibiotics for medical indications such as chorioamnionitis among participants with ROM.
Study participants were randomized to receiving postoperative cephalexin-metronidazole (n = 202 participants) or identical placebo (n = 201 participants). Maternal demographic, medical, and surgical characteristics of the study population are summarized in Table 1 .
Of the 404 participants randomized, 382 (94.6%) completed the trial, 357 (88.1%) completed the medication regimen without deviation, 12 (3.0%) voluntarily withdrew from the study before the first medication administration or prior to completion of the scheduled regimen, and 43 (10.6%) had 1 or more drug administration deviations. Of the medication administration deviations, 22 (51.2%) were attributable to participants missing the last dose of study drug secondary to hospital discharge. Twenty-one (5.2%) of 404 participants could be reached only by telephone and were not examined during follow-up. The cephalexinmetronidazole and placebo groups had similar rates of loss to follow-up (5.0% vs 5.9%, respectively; difference, 0.5%; 95% CI, −3.8% to 4.9%; P = .81).
Study Outcomes
The overall rate of SSI, the primary outcome, was 10.9% (95% CI, 7.9%-14.0%) in the study population, occurring in 13 (6.4%) of 202 women who received a postoperative course of cephalexin-metronidazole vs 31 (15.4%) of 201 women in the placebo group (difference, 9.0%; 95% CI, 2.9%-15.0%; P = .01). The relative risk (RR) of SSI in the antibiotic group compared with the placebo group was 0.41 (95% CI, 0.22-0.77) ( Table 2 ). Considering the influence of missing data, multiple imputation analysis of the primary outcome estimated an absolute between-group difference in rates of SSI with antibiotics vs placebo of 10.9% (95% CI, 6.1%-15.7%) and an RR of 0.36 (95% CI, 0.23-0.57), which were consistent with the original analysis. The number needed to treat to prevent 1 SSI in all obese women undergoing cesarean delivery was 12 (95% CI, 6.7-33.8).
Prespecified secondary outcomes are also shown in Table 2 . Cellulitis was the only secondary outcome with a significant reduction with prophylactic antibiotics, occurring in 12 of 202 (5.9%; 95% CI, 2.7%-9.2%) participants who received metronidazole-cephalexin vs 27 of 201 (13.4%; 95% CI, 8.9%=18.2%) participants who received placebo (mean difference, 7.5% [95% CI, 1.7%-13.0%]; RR, 0.44 [95% CI, 0.23-0.84]). There were no significant differences between cephalexin-metronidazole and placebo for the other prespecified secondary outcomes, including rates of incisional morbidity, fever of unknown etiology, wound separation, or endometritis.
There were no serious adverse events or allergic reactions reported for cephalexin or metronidazole. Twelve patients voluntarily withdrew from participation, 4 (2%) in the antibiotic group and 8 (4%) in the placebo group, and nausea was the most commonly reported reason for study discontinuation.
Post hoc subgroup analyses were conducted among patients with and without ROM ( Table 3) . Randomized participants who had ROM comprised 31.5% (64/203) of the cephalexin-metronidazole group and 31.3% (63/201) of the placebo group (difference, 0.2%; 95% CI, −8.9% to 9.3%; P =. 97). Among participants with ROM prior to delivery, the cephalexinmetronidazole and placebo groups demonstrated no significant difference, respectively, in the duration of ROM (median, 11 [interquartile range, 5-18] hours vs 6 [interquartile range, 4-15] hours; P = .69) or in the frequency of internal monitoring (fetal scalp electrode: 59.4% vs 47.4%; difference, 3.2% [95% CI, −14.3% to 20.7%]; P = .80; intrauterine pressure catheter: 60.9% vs 66.7%; difference, 6.3% [95% CI, −10.7% to 23.4%]; P = .50; and amnio-infusion: 12.5% vs 14.3%; difference, 1.6% [95% CI, −10.6% to 13.7%]; P =. 77).
The rate of SSI was 19.8% among women with ROM and 6.9% among those with intact membranes [difference, 13.9%; 95% CI, 12.8%-26.9%; P < .001). Post hoc analysis revealed that among participants with ROM prior to cesarean delivery, SSI occurred in 6 (9.5%) of 60 in the cephalexinmetronidazole group and 19 (30.2%) of 58 in the placebo group (difference, 22.8%; 95% CI, 8.3%-37.2%; P = .008). Among participants with intact membranes, SSI occurred in 7 (5.0%) of 132 in the cephalexin-metronidazole group compared with 12 (8.7%) of 132 in the placebo group (difference, 3.8%; 95% CI, −2.5% to 10.1%; P = .47). Interaction testing was performed between study groups (cephalexinmetronidazole vs placebo) and by membrane status (intact vs ROM) (eTable 2 in Supplement 2). The rate of SSI was highest in those with ROM who received placebo (30.2%) and lowest in those with intact membranes who received antibiotics (5.0%), but the test for interaction did not show statistical significance at P =.30.
Discussion
In this clinical trial involving obese women undergoing cesarean delivery after receiving standard intravenous preoperative cefazolin prophylaxis, a 48-hour postoperative course of oral cephalexin-metronidazole, compared with placebo, significantly decreased the rate of SSI within 30 days after delivery. Among the secondary outcomes measured, patients treated with cephalexin-metronidazole had lower rates of cellulitis but no significant decrease in other secondary outcomes, including rates of incisional morbidity, fever of unknown etiology, wound separation, or endometritis. Cephalexin-metronidazole therapy has broad-spectrum antibiotic coverage and has demonstrated efficacy in the treatment of intra-abdominal infections in nonobstetric patients as well as decreased postcesarean infections when given preoperatively. 15, 24 Obesity is associated with comorbidities, anatomical factors (ie, skin folds and increased tissue pressure), and bioactive adipose tissue that increase the risk of SSI. 25 Adipose tissue is highly active and secretes a wide range of hormone factors, chemokines, and, importantly, cytokines, regulating inflammation and oxidative stress. 26 In addition to greater anaerobic coverage, metronidazole has antiinflammatory properties and the antimicrobial activity of metronidazole's hydroxymetabolite against common isolates associated with postcesarean infections, including
Mycoplasma, Ureaplasma, and Gardnerella species.
14,27,28
Cephalexin and metronidazole have high oral bioavailability and pharmacoeconomic advantages and are generally well tolerated, supporting the drug combination as a choice for postpartum prophylactic coverage.
29 A 48-hour time course for prophylaxis was chosen considering the biological stages of wound healing. After the initial 1-to 2-day hemostatic and inflammatory phases of healing, the proliferation period occurs and includes epithelization, angiogenesis, and granulation tissue formation. This period is critical for the proper deposition of fibroblasts, basement membrane organization, and collagen formation. 30 Because regulation of this inflammatory phase is important for the remodeling periods of healing, we chose a 48-hour course of prophylactic antibiotics to provide coverage while reepithelialization occurs. This study was the first to our knowledge to evaluate the use of a prophylactic postcesarean course of cephalexinmetronidazole for prevention of SSI in an obese population. Cellulitis was the most frequent incisional morbidity observed in the study and had improved rates of SSI among studies included women of all BMI categories, took place in low-resource areas, had higher proportions of immunocompromised participants, were underpowered, and were confounded by significant nutritional challenges, which are not generalizable to our population. The use of additional broad-spectrum antibiotics has been shown to reduce SSI in women in all BMI categories undergoing cesarean delivery. Tita et al 5 demonstrated a decrease (RR, 0.51; 95% CI, 0.38-0.68; P < .001) in postcesarean SSI by expanding the preoperative antimicrobial spectrum with azithromycin among women in labor and those with ROM but not specifically among obese women. These study results were published in the final year of the current study enrollment period, and azithromycin was chosen to increase coverage of Mycoplasma isolates. Although this study targeted prepregnancy obesity and the C/SOAP Consortium study focused on women in labor as the high-risk cohort, 5 there is considerable population overlap, and both studies demonstrated similar and significant reductions in SSI. Obesity during pregnancy has been associated with numerous adverse maternal and fetal outcomes such as macrosomia, cesarean delivery, and cerebral palsy.
34-36
In addition, obese women who have medical or perinatal complications are less likely to initiate or will prematurely discontinue breastfeeding. 37 Although both cephalexin and metronidazole are detected in breast milk in low concentrations, previous studies have not demonstrated any serious adverse outcomes with cephalexin or metronidazole used as single or combination therapy. 38-40 Long-term childhood or adverse neonatal outcomes specific to cephalexinmetronidazole exposure cannot be determined, as outcome measures were not evaluated for this study protocol. Recognizing the maternal and neonatal benefit of breastfeeding, the lack of known neonatal adverse effects, and maternal reduction in SSI, the benefit of this antibiotic regimen likely outweighs the theoretical risks of breast milk exposure in the obese population.
This study has several strengths. First, the study used a randomized, blinded design; included representation of a diverse, high-risk patient population; and included a relatively large cohort of obese participants. Second, the primary outcome of interest is a significant health careassociated infection that is common and preventable. Although prior studies have demonstrated undergoing labor prior to delivery significantly increased postoperative infections after cesarean deliveries among all BMI categories, these studies were not focused to the obese population nor stratified by membrane status prior to delivery. 3, 21 Third, the magnitude of the reduction of SSI with postcesarean delivery related to antibiotic prophylaxis in this population (RR, 0.41; 95% CI, 0.22-0.77) is both statistically significant and clinically meaningful. This study also has several limitations. First, the trial was performed at a single site with a high prevalence of obesity, which may not be generalizable to all obstetric practices. Second, women diagnosed as having chorioamnionitis were excluded from study enrollment because they represent a separate risk population. The current study design was unable to assess efficacy among this population. Third, the analyses did not account for multiple comparisons and subgroup interactions, so all secondary outcomes and findings based on stratification of intact or ruptured membranes should be considered exploratory and hypothesis generating. Fourth, this study had insufficient power to determine a significant reduction in SSI in the subgroup of women with intact membranes. The majority of women with intact membranes had scheduled cesarean deliveries and did not have contractions resulting in cervical change, and only 7% of women in this study went into labor with intact membranes prior to cesarean delivery. Hence, the efficacy of prophylactic postpartum antibiotics in this subgroup cannot be determined from the current study, but the findings provide support to promote further study of this subset of participants. Fifth, this trial included a very specific population of women with prepregnancy obesity undergoing cesarean delivery, and the findings should not be extrapolated to other populations or other surgical procedures. Sixth, enrollment was terminated before target recruitment was met (targeted: n=438; actual: n=404) secondary to a predetermined stop date; however, a lower rate of attrition was experienced (10% projected; 5% actual). Seventh, adverse events were monitored per institutional review board protocol, but data regarding more specific minor adverse effects were not collected unless reported by participants.
Conclusions
Among obese women undergoing cesarean delivery who received standard preoperative cephalosporin prophylaxis, a postoperative 48-hour course of cephalexin-metronidazole, compared with placebo, reduced the rate of SSI within 30 days of delivery. For prevention of SSI among obese women after cesarean delivery, prophylactic oral cephalexin and metronidazole may be warranted. Chlorhexidine skin decontamination will be the standard surgical site preparation. An 217 antimicrobial, adhesive drape will be used with sterile technique. Prior to skin incision, 2 218 grams of cefazolin will be administered. 219
In general, use of excessive electrocautery will be discouraged as devitalization 220 of tissue is a known risk factor for postsurgical infection. After delivery of the fetus, the 221 uterus will be repaired in a standard technique. After hemostasis has been achieved, 222 irrigation of the peritoneal cavity including the paracolic gutters will be performed with 223 warmed saline in a standard fashion. The fascia will be reapproximated with a 224 monofilament suture, preferable 0 Maxon suture, in a running stitch. Hemostasis will be 225 achieved in the abdominal wall incision with sutures and electrocautery, again limiting 226 excessive use of electrocautery as is surgically feasible. This potential subcutaneous 227 adipose tissue dead space will then be reapproximated with 3-0 polyglacton in either a 228 running or interrupted stitch. It will be encouraged to close the skin with a subcuticular 229 stich. Subcutaneous surgical drains will not be used as they have been found to not 230 decrease rate of wound infections. 231
There may be a relationship between type of incision and rate of postoperative 232 infectious complications. However, the type of incision, Pfannenstiel versus a vertical 233 skin incision, is very dependent upon individual body habitus, prior incisions, and 234 surgeon preferences. Given the complexity involved in determining the optimal method 235 of skin incision for a particular clinical situation, this will be left to the discretion of the 236 primary surgeon. 237 All patients will be followed after delivery in a routine fashion. The surgical 238 dressing will be removed 24-36 hours post operation. The staples, if used, will be 239 removed on postoperative day 3-4 for Pfannenstiel skin incisions day 5-6 for vertical 240 skin incisions. The incision will be daily and final examination on day of discharge for 241 signs of infection in all study patients. In addition, patients will be asked to return in two 242 weeks for a postoperative check. Any signs of infection will be noted at that time. 243
Finally, six weeks after surgery at the traditional postpartum check, the incision will be 244 inspected for evidence of a wound infection. Study participants will be encouraged to 245 notify research staff if concerns for an infection arise outside of these postpartum visits. 246
If participants are noncompliant with the scheduled follow-up examinations, the 247 research staff will attempt to reach the participant and encourage her return for 248 examination and assess for any concerning signs of infection. If the participant refuses 249 or is unable to come in for clinical evaluation, she will be questioned regarding: pain at 250 incision site, drainage from incision, fever, separation of the incision, or any unexpected 251 evaluation at an urgent or emergency care facility. Warshak). Further information regarding wound complications will be collected on the 312 data collection sheet. Once the patient has reached six weeks out, this sheet will be 313 reviewed for completion. If the study participant has not followed up, the patient will be 314 called as described above. 315
Once the data collection sheet is completed, it will be stored in a locked cabinet 316 in the secured office of the PI. The data will be entered in to the REDCap database, 317 which is secure, web based application designed to support data capture for research 318 studies. After data is entered into REDCap, the datasheets will be discarded in 319 appropriate secure confidential document receptacles per the University of Cincinnati 320
Medical Center protocols. The data will remain blinded until all analyses are completed 321 by Emily DeFranco who will blinded to study group designation and not involved in 322 study recruitment or data collection. At this time, all data will be unblinded, entered into 323 SPSS software package spreadsheets for evaluation and analyzed. Statistical analysis 324 will be performed using STATA software (STATA, release 12; Stata-Corp, College 325 Station, TX USA). 326 Demographic characteristics will be compared between women who received 327 cephalexin-metronidazole and placebo using one-way ANOVA for continuous variables 328
and Chi square tests for categorical variables. Logistic regression will be used to 329 determine the relative risk of SSI between women who received cephalexin-330 metronidazole compared to placebo, and the number needed to treat to prevent one 331 SSI will be calculated. The analysis will be performed with an intention to treat principle. 332
Comparisons with a probability value <0.05 or 95% confidence interval without inclusion 333 of the null were considered statistically significant. 334 335 e. Data Storage and Confidentiality: 336 337 All data will be deidentified for the purposes of protecting of study participant 338 confidentiality. Data collection sheets and subsequent spreadsheets will therefore be 339 removed of any identifying information. These hard paper copies and electronic 340 spreadsheets will remain on the University of Cincinnati Medical Center and College of 341
Medicine property throughout the duration of the study. Because obese women have a significant risk for post-cesarean infection, broad 371 spectrum postpartum antibiotics may decrease their risk for significant morbidity and 372 costs associated with treatment of these uterine and wound infections. Often patients 373 are admitted for many extra days, readmitted and require extensive use of home health 374 care resources because of these common complications. This impacts not only mother-375 baby bonding but breastfeeding and overall recovery. If we are correct in our 376 predictions regarding the substantial reduction in these complications there will be no 377 question as to the benefit to patient care in this high risk population. Given the current 378 rates of obesity in our country this will undoubtedly prove to be both a beneficial and 379 cost-effective prevention strategy. 380
In comparison to the minimal risks stated above, the potential benefit far 381 outweighs these risks. We must begin to understand how to treat our obese population 382 better. This is especially true in the obstetrical population that has traditionally been 383 considered low risk for medical complications given the perception women reproducing 384 are healthy. While fortunately this is true in many instances, obese women are far from 385 healthy and we know how obesity increases many significant complications of 386 pregnancy. Obese women have much higher rates of cesarean delivery and 387 postoperative infectious complications. Research to figure out how to ideally manage 388 and prevent these complications is needed. 389 390 Payment: Study participants will not be paid for their participation in this project. 391 392
